Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 5(42), p. 571-583, 2024
DOI: 10.1200/jco.23.00339
Links
Tools
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial
Journal article published in 2024 by
Joaquin Mateo 
,
Johann S. de Bono ,
Karim Fizazi ,
Fred Saad ,
Neal Shore ,
Shahneen Sandhu ,
Kim N. Chi ,
Neeraj Agarwal ,
David Olmos ,
Antoine Thiery-Vuillemin,
Mustafa Özgüroğlu ,
Niven Mehra ,
Nobuaki Matsubara,
Jae Young Joung ,
Charles Padua
and other authors.
,
Johann S. de Bono ,
Karim Fizazi ,
Fred Saad ,
Neal Shore ,
Shahneen Sandhu ,
Kim N. Chi ,
Neeraj Agarwal ,
David Olmos ,
Antoine Thiery-Vuillemin,
Mustafa Özgüroğlu ,
Niven Mehra ,
Nobuaki Matsubara,
Jae Young Joung ,
Charles Padua
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.